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Purpose: It is well established that patients with knee osteoarthri-
tis (OA) exhibit marked muscle weakness, commonly associated
with the quadriceps muscle group. Conversely, there is evidence
that a strong quadriceps muscle may protect both against further
joint damage in established OA and be a protective factor in the
initiation of OA. Numerous studies have shown that exercises
aimed at improving the quadriceps muscle have beneﬁcial effects
in OA patients, which include reduced knee pain and increased
physical ability. However, improving skeletal muscle strength and
functional performance through intensive exercise regimes is often
inappropriate or contra-indicated for the majority of OA patients
who are elderly, overweight, co-morbid and may be frail. To this
end we explored whether the beta2-adrenergic agonist clenbuterol,
which in terms of its hypertrophic effects in skeletal muscle is well
characterised, was able to modify the progression of OA in a
meniscectomy (MNX) induced rodent model. The impact of clen-
buterol administration prior to meniscectomy surgery was investi-
gated in terms of skeletal muscle hypertrophy, joint histopathology
and behavioural pain.
Methods: A total of 35 male Lewis rats (280.37g±1.69) were sub-
cutaneously administered with 1.5mg/kg clenbuterol HCl (n=15)
or saline vehicle (n=20) for 14 days. Following pre-treatment, 5
animals from each group were sacriﬁced to assess the immediate
effects of clenbuterol. The remaining animals underwent either
MNX surgery (clenbuterol pre-treated n=10; saline pre-treated
n=10) or a sham control surgical procedure (saline pre-treated
n=5). OA was induced by transection of the medial collateral liga-
ment and medial meniscus. During disease initiation and progres-
sion, gait and behavioural pain were assessed by incapacitance
analysis. Myosin heavy chain isoforms (MHC) were quantiﬁed by
silver stained SDS PAGE gel electrophoresis and OA severity
was graded by assessment of toluidine blue stained step coronal
sections.
Results: Administration of clenbuterol for 2 weeks resulted in a
signiﬁcant increase in total bodyweight (p= < 0.001), growth rate
(p= 0.002) and in quadriceps muscle mass (p= <0.001) relative
to those rats receiving saline vehicle. MHC isoform protein ex-
pression showed that the rat quadriceps muscle is predominantly
composed of fast twitch myosin, with a composition of 4.85% type
I, 7.25% type IIA, 22.34% type IIX and 66.55% type IIB. Clen-
buterol administration exhibited an apparent 16% increase in total
MHC protein expression relative to total protein; however clen-
buterol administration for 14 days did not change the composition
of the different MHC isoforms, suggesting that ﬁbre composition
was not altered. MNX surgery resulted in the development of OA
like lesions on both the tibial and femoral condyles. OA develop-
ment was associated with gait changes indicative of behavioural
joint pain, in addition to an apparent increase in MHC type I
protein expression. Clenbuterol induced hypertrophy of skeletal
muscle (quadriceps +40%, p= <0.001) had no signiﬁcant effect on
either gait or the severity of articular pathology following MNX.
Conclusions: Our data reveal that clenbuterol induced skeletal
muscle hypertrophy is unable to mimic the previously reported ben-
eﬁcial effects of increased musculature derived through targeted
strength training, in a rodent model of meniscectomy induced OA.
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Purpose: The relationship of structural changes in OA and clinical
outcomes, such as pain, is of high interest for imaging biomarker
validation. A wide range of MRI-based features, such as bone
marrow lesions, have been investigated. One recent study showed
a signiﬁcant relationship of denuded bone areas (dABs), measured
with MRI, with the existence and the incidence of knee pain in OA.
In the absence of a friction-less cartilage surface, peak pressures
and shear forces occurring during weight-bearing may generate
pain in the richly innervated bone tissue. This may be most
relevant in central femorotibial subregions, where the meniscus
is not involved in pressure distribution. We therefore investigated
whether dABs are more closely related to weight-bearing (WB)
than non-weight-bearing (NWB) pain, and whether dABs in central
locations of the femorotibial cartilages are more strongly related
to pain than “any” dAB, including peripheral locations.
Methods: A subsample of the OAI (public-use data sets 0.2.1
[clinical] and 0.C.1 [image data]) (n=537; 211 male; 326 female;
age 62.1±9.7 y.; 41 KLG 0/1 [calculated from osteophyte and
JSN scores]; 239 KLG2; 235 KLG3; 22 KLG4; BMI 29.7±4.6
kg/m2; public data releases 0.E.1 and 1.E.1) was studied. Manual
segmentation of the femorotibial cartilages (MT, LT, cMF, cLF)
was performed on baseline MRI acquisitions, including dABs.
These were deﬁned as subchondral bone areas not covered by
cartilage, delineated in more than one 1.5mm slice. dABs in “any”
region or in central subregions of the medial and lateral tibia and
femur were analyzed. Self-reported pain frequency was assessed
based on item P1 of the Knee injury and Osteoarthritis Outcome
Score (KOOS) pain subscore. As previously suggested, WB pain
intensity was assessed based on Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) LK 3.1 pain subscale
questions #1 (walking) & #2 (stairs). NWB pain intensity was based
on questions #3 (night) & #4 (sitting). The relationship between
dABs and pain was analyzed using univariate (Mann-Whitney) and
multivariate tests (general linear models), comparing “any” dAB
with no dAB, and “central” dAB with no dAB.
Results: 214 of the 537 knees displayed “any” dAB and 63 of
those “central” dABs; 118 knees were never painful, but 419
had pain at least monthly (KOOS item P1). Knee pain frequency
was signiﬁcantly related to “any” femorotibial dAB (p= 0.02 for
univariate analysis and p=0.01 (r2=6.5%) after correcting for sex,
age and BMI) and to “central” dAB (p=0.04 and 0.001/r2=8.2%),
respectively). WB pain intensity showed borderline signiﬁcance
with “any“ dAB (p=0.06 and 0.04; r2=9.6%) and a signiﬁcant
relationship with “central” dABs (p=0.03 and 0.002; r2=10.9%).
NWB pain was not signiﬁcantly related to “any” dAB (p=0.20 and
0.28; r2=6.6%) or “central” dAB (p=0.051 and 0.09; r2=6.5%).
The r2 values for WB pain and central dABs were, however, not
